Association of IL-2RA and IL-2RB genes with erosive status in early rheumatoid arthritis patients (ESPOIR and RMP cohorts)

Joint Bone Spine

Volumn 81, Issue 3, 2014, Pages 228-234

  Ruyssen Witrand, Adeline ^a,b,c   Lukas, Cedric ^d   Nigon, Delphine ^c   Dawidowicz, Karen ^e   Morel, Jacques ^d   Sibilia, Jean ^f   Jamard, Bénédicte ^c   Cambon Thomsen, Anne ^a,b   Cantagrel, Alain ^b,c,g   Dieudé, Philippe ^a,e,h   Constantin, Arnaud ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

^c CHU PURPAN   (France)

^d LAPEYRONIE HOSPITAL   (France)

^e BICHAT HOSPITAL   (France)

^f HÔPITAL DE HAUTEPIERRE   (France)

^g University of Toulouse III   (France)

^h UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Autoantibodies; Disease progression; IL 2RA; IL 2RB; Rheumatoid arthritis; Single nucleotid polymorphism

Indexed keywords

INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 2 RECEPTOR BETA; DISEASE MODIFYING ANTIRHEUMATIC DRUG; LEFLUNOMIDE; METHOTREXATE;

ADULT; ARTICLE; COHORT ANALYSIS; DISEASE ASSOCIATION; EROSION; FEMALE; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; AGE; CLINICAL EXAMINATION; DISEASE DURATION; FOLLOW UP; FOOT RADIOGRAPHY; GENETIC ASSOCIATION; HAND RADIOGRAPHY; META ANALYSIS (TOPIC); SMOKING HABIT;

AUTOANTIBODIES; DISEASE PROGRESSION; IL-2RA; IL-2RB; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTID POLYMORPHISM;

ADULT; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; INTERLEUKIN-2 RECEPTOR BETA SUBUNIT; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84901476705     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2013.10.002     Document Type: Article

References (32)

1. Dadoun S., Zeboulon-Ktorza N., Combescure C., et al. Mortality in rheumatoid arthritis over the last fifty years: systematic review and meta-analysis. Joint Bone Spine 2013, 80:29-33.
2. MacGregor A.J., Snieder H., Rigby A.S., et al. Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum 2000, 43:30-37.
3. van der Helm-van Mil A.H., Kern M., Gregersen P.K., et al. Variation in radiologic joint destruction in rheumatoid arthritis differs between monozygotic and dizygotic twins and pairs of unrelated patients. Arthritis Rheum 2006, 54:2028-2030.
4. Karlson E.W., Chang S.C., Cui J., et al. Gene-environment interaction between HLA-DRB1 shared epitope and heavy cigarette smoking in predicting incident rheumatoid arthritis. Ann Rheum Dis 2010, 69:54-60.
5. Fakhfakh Karray E., Chalbi H., Ben Dhifallah I., et al. Association study of TRAF1-C5 polymorphism with susceptibility to rheumatoid arthritis in Tunisian population. Joint Bone Spine 2012, 79:331-332.
6. Plant D., Flynn E., Mbarek H., et al. Investigation of potential non-HLA rheumatoid arthritis susceptibility loci in a European cohort increases the evidence for nine markers. Ann Rheum Dis 2010, 69:1548-1553.
7. Farragher T.M., Lunt M., Plant D., et al. Benefit of early treatment in inflammatory polyarthritis patients with anti-cyclic citrullinated peptide antibodies versus those without antibodies. Arthritis Care Res 2010, 62:664-675.
8. van der Helm-van Mil A.H., Verpoort K.N., Breedveld F.C., et al. Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Res Ther 2005, 7:R949-R958.
9. Ceccarelli F., Perricone C., Fabris M., et al. Transforming growth factor beta 869C/T and interleukin 6-174G/C polymorphisms relate to the severity and progression of bone-erosive damage detected by ultrasound in rheumatoid arthritis. Arthritis Res Ther 2011, 13:R111.
10. Ohmura K., Terao C., Maruya E., et al. Anti-citrullinated peptide antibody-negative RA is a genetically distinct subset: a definitive study using only bone-erosive ACPA-negative rheumatoid arthritis. Rheumatology (Oxford) 2010, 49:2298-2304.
11. Gesbert F., Sauvonnet N., Dautry-Varsat A. Clathrin-lndependent endocytosis and signalling of interleukin 2 receptors IL-2R endocytosis and signalling. Curr Top Microbiol Immunol 2004, 286:119-148.
12. Ma A., Koka R., Burkett P. Diverse functions of IL-2, IL-15, and IL-7 in lymphoid homeostasis. Annu Rev Immunol 2006, 24:657-679.
13. Sadlack B., Merz H., Schorle H., et al. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 1993, 75:253-261.
14. Suzuki H., Kundig T.M., Furlonger C., et al. Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor beta. Science 1995, 268:1472-1476.
15. Willerford D.M., Chen J., Ferry J.A., et al. Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment. Immunity 1995, 3:521-530.
16. Sharfe N., Dadi H.K., Shahar M., et al. Human immune disorder arising from mutation of the alpha chain of the interleukin-2 receptor. Proc Natl Acad Sci U S A 1997, 94:3168-3171.
17. Wang J., Wicker L.S., Santamaria P. IL-2 and its high-affinity receptor: genetic control of immunoregulation and autoimmunity. Semin Immunol 2009, 21:363-371.
18. Oh S., Rankin A.L., Caton A.J. CD4+CD25+ regulatory T-cells in autoimmune arthritis. Immunol Rev 2010, 233:97-111.
19. Wellcome Trust Case Control Consortium Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007, 447:661-678.
20. Kurreeman F.A., Daha N.A., Chang M., et al. Association of IL2RA and IL2RB with rheumatoid arthritis: a replication study in a Dutch population. Ann Rheum Dis 2009, 68:1789-1790.
21. Yang H.C., Liang Y.J., Chung C.M., et al. Genome-wide gene-based association study. BMC Proc 2009, 3:S135.
22. Barton A., Thomson W., Ke X., et al. Rheumatoid arthritis susceptibility loci at chromosomes 10p15, 12q13 and 22q13. Nat Genet 2008, 40:1156-1159.
23. Prasad P., Kumar A., Gupta R., et al. Caucasian and Asian specific rheumatoid arthritis risk loci reveal limited replication and apparent allelic heterogeneity in north Indians. PloS One 2012, 7:e31584.
24. Combe B., Benessiano J., Berenbaum F., et al. The ESPOIR cohort: a ten-year follow-up of early arthritis in France: methodology and baseline characteristics of the 813 included patients. Joint Bone Spine 2007, 74:440-445.
25. Arnett F.C., Edworthy S.M., Bloch D.A., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324.
26. Cantagrel A., Navaux F., Loubet-Lescoulie P., et al. Interleukin-1beta, interleukin-1 receptor antagonist, interleukin-4, and interleukin-10 gene polymorphisms: relationship to occurrence and severity of rheumatoid arthritis. Arthritis Rheum 1999, 42:1093-1100.
27. Constantin A., Dieude P., Lauwers-Cances V., et al. Tumor necrosis factor receptor II gene polymorphism and severity of rheumatoid arthritis. Arthritis Rheum 2004, 50:742-747.
28. Constantin A., Navaux F., Lauwers-Cances V., et al. Interferon gamma gene polymorphism and susceptibility to, and severity of, rheumatoid arthritis. Lancet 2001, 358:2051-2052.
29. Prevoo M.L., van't Hof M.A., Kuper H.H., et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995, 38:44-48.
30. van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 1999, 26:743-745.
31. Lukas C., Combe B., Ravaud P., et al. Favorable effect of very early disease-modifying anti-rheumatic drug treatment on radiographic progression in early inflammatory arthritis: Data from the Etude et Suivi des polyarthrites indifferenciees recentes (study and followup of early undifferentiated polyarthritis). Arthritis Rheum 2011, 63:1804-1811.
32. Stahl E.A., Raychaudhuri S., Remmers E.F., et al. Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat Genet 2010, 42:508-514.